PIK3CA mutations attenuate the antiproliferative effects of a HER2 inhibitor and an AKT inhibitor enhances the antiproliferative activity of a HER2 inhibitor in PIK3CA-mut HER2+ breast cancer cell lines. This evidence concerns the gene ERBB2 and breast carcinoma.